Major Pharmaceuticals recalled 866 blister packs of Chlorpromazine Hydrochloride Tablets on September 12, 2025. The recall follows the detection of N-Nitroso Desmethyl Chlorpromazine above safe limits. The affected products were distributed nationwide and are classified as a Class II hazard.
CGMP Deviations: Presence of N-Nitroso Desmethyl Chlorpromazine above the recommended intake limit
Consumers and healthcare providers should stop using this product immediately. Contact The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall affects Chlorpromazine Hydrochloride Tablets, USP, 100 mg, packaged in 100 tablets per blister pack. The recalled lots include N01920, N02023, and N02202, with expiration dates of December 31, 2025, February 28, 2026, and June 30, 2026 respectively. The products were distributed nationwide.
The recall stems from CGMP deviations, specifically the presence of N-Nitroso Desmethyl Chlorpromazine at levels above the recommended intake limit. This contaminant poses potential health risks to consumers.
No specific incidents of injury or illness linked to this product have been reported at this time. The hazard level is classified as high due to the potential health implications associated with the contaminant.
Consumers and healthcare providers should stop using the recalled product immediately. Contact The Harvard Drug Group LLC or your healthcare provider for further guidance.
For questions, consumers can reach The Harvard Drug Group LLC at their website or by contacting their customer service.
Get instant alerts for recalls that affect you. Free forever.
Glenmark Pharmaceuticals recalled nearly 97,000 packs of Ondansetron Orally Disintegrating Tablets on December 30, 2025. Defective blister packs may not fully seal, leading to tablets falling out. Consumers should stop using the product immediately and contact healthcare providers.
Novo Nordisk recalled Wegovy (semaglutide) injections on December 19, 2025, after discovering hair in prefilled syringes. The contamination poses a serious hazard to consumers. The recall affects all units distributed nationwide.
Novo Nordisk recalled Wegovy (semaglutide) Injection on December 19, 2025, due to hair found in a prefilled syringe. The recall affects products distributed nationwide in the United States. Consumers should stop using the product immediately and contact their healthcare provider.
Zydus Pharmaceuticals recalled over 2,100 bottles of TraZODONE Hydrochloride Tablets on December 19, 2025. Some tablets have surface dents that may affect medication integrity. Consumers should stop using the product immediately and seek guidance from healthcare providers.
CareFusion 213, LLC recalled 106,400 units of ChloraPrep Triple Swabsticks on December 17, 2025. The recall occurred due to a lack of assurance of sterility. Consumers must stop using the product immediately and contact CareFusion for guidance.
Merck Sharp & Dohme LLC recalled 845 kits of Noxafil Powdermix on December 12, 2025. The recall follows the discovery of potential metal particulates in the product. Consumers should stop using the medication immediately and contact their healthcare provider for further guidance.
Merck Sharp & Dohme LLC recalled 3 single-dose kits of Emend (aprepitant) on December 12, 2025. The recall stems from the potential presence of metal particulates in the medication. Consumers should immediately stop using the product and contact their healthcare provider for guidance.
Beaver-Visitec International recalled five units of the OME6000U Laser and Endoscopy System on December 5, 2025. The recall stems from a manufacturing deviation where ferrites required for the USB cable were not installed. This omission poses a high electrical hazard risk to patients and healthcare providers.